Source comparison
The Comparative Truth About CJC-1295 vs GHRP-2 Acetate
Here's the honest answer: most researchers choose CJC-1295 vs GHRP-2 Acetate based on dosing convenience rather than mechanistic fit. Weekly injections are easier to manage than multiple daily doses, so CJC-1295 gets selected by default. Even when the research
This comparison does not assign a generated winner or score.
- Here's the honest answer: most researchers choose CJC-1295 vs GHRP-2 Acetate based on dosing convenience rather than mechanistic fit. Weekly injections are easier to manage than multiple daily doses, so CJC-1295 gets selected by default. Even when the research question demands acute pulsatility that only GHRP-2 can provide. The protocols that produce the most dramatic, reproducible outcomes don't choose one or the other. They use both, because GHRH receptor activation and ghrelin receptor stimulation are synergistic pathways that were never meant to be separated. Single-peptide studies underperform combination protocols in every published metric related to GH secretion, IGF-1 elevation, lean mass accretion, and lipolysis. If your research infrastructure can support twice-daily GHRP-2 injections alongside weekly CJC-1295 dosing, that's the protocol design with the strongest evidentiary support. Not one or the other, both simultaneously.